NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
NEOGENOMICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$16.42−0.23 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $2.15B
- P/E (TTM)
- –
- Dividend yield
- –
Neogenomics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Testing Laboratories companies for comparison
Valuation
| Measure | Neogenomics | Industry median |
|---|---|---|
| Market Cap | $2.11B | $73.61M |
| Enterprise Value | $2.34B | $55.54M |
| PS Ratio | 2.75 | 3.25 |
| PB Ratio | 2.68 | 3.13 |
| P/OCF Ratio | 95.68 | 15.81 |
Enterprise value
| Measure | Neogenomics | Industry median |
|---|---|---|
| EV / Sales | 3.05 | 2.79 |
Income (trailing twelve months)
| Measure | Neogenomics | Industry median |
|---|---|---|
| Revenue | $766.30M | $24.74M |
| Gross Profit | $336.53M | $19.54M |
| Operating Income | -$68.44M | -$55.64K |
| Pretax Income | -$54.55M | $45.62K |
| Net Income | -$51.88M | -$97.64K |
| EBITDA | -$68.44M | -$29.48K |
| EPS (Diluted) | -$0.40 | $0.00 |
Margins
| Measure | Neogenomics | Industry median |
|---|---|---|
| Gross Margin | 43.9% | 40.4% |
| Operating Margin | -8.93% | 0.94% |
| Pretax Margin | -7.12% | 2.64% |
| Profit Margin | -6.77% | 0.51% |
| EBITDA Margin | -8.93% | 3.48% |
| FCF Margin | -0.96% | 5.05% |
Returns
| Measure | Neogenomics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -6.33% | 0.45% |
| Return on Assets (ROA) | -3.78% | -3.47% |
| Return on Invested Capital (ROIC) | -6.31% | 2.85% |
| Return on Capital Employed (ROCE) | -5.49% | 2.03% |
Growth
| Measure | Neogenomics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.2% | 4.26% |
| Revenue Growth (3Y CAGR) | 12.6% | 2.15% |
| Revenue Growth (5Y CAGR) | 10.4% | 7.37% |
Balance sheet
| Measure | Neogenomics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $145.54M | $5.43M |
| Total Debt | $374.24M | $85.44M |
| Net Cash (Debt) | -$228.70M | $17.62K |
| Net Cash Per Share | -$1.78 | $0.00 |
| Equity (Book Value) | $785.73M | $10.50M |
| Book Value Per Share | $6.12 | $0.60 |
| Tangible Book Value | -$9.53M | -$78.36K |
| Working Capital | $275.60M | $2.78M |
Financial position
| Measure | Neogenomics | Industry median |
|---|---|---|
| Current Ratio | 3.60 | 1.26 |
| Quick Ratio | 3.03 | 0.65 |
| Debt / Equity | 0.48 | 0.45 |
| Interest Coverage | -26.52 | -0.23 |
Cash flow (trailing twelve months)
| Measure | Neogenomics | Industry median |
|---|---|---|
| Operating Cash Flow | $22.05M | $8.04K |
| Capital Expenditures | -$29.40M | -$8.33M |
| Free Cash Flow | -$7.36M | $11.03M |
| FCF Per Share | -$0.06 | $0.76 |
Efficiency
| Measure | Neogenomics | Industry median |
|---|---|---|
| Asset Turnover | 0.56 | 0.83 |
| Inventory Turnover | 14.02 | 13.10 |
| Revenue Per Employee | $306.52K | $216.23K |
| Profits Per Employee | -$20.75K | -$1.99K |
| Employee Count | 2,500 | 115 |
Dividends and yields
| Measure | Neogenomics | Industry median |
|---|---|---|
| Earnings Yield | -2.46% | -1.29% |
| FCF Yield | -0.35% | 3.90% |
| Buyback Yield | -0.02% | 1.36% |
| Shareholder Yield | -0.02% | 1.65% |
Shares
| Measure | Neogenomics | Industry median |
|---|---|---|
| Shares Outstanding | 128,475,000 | 29,217,800 |
| Shares Change (YoY) | 1.50% | 0.84% |
| Shares Change (QoQ) | -1.34% | 0.00% |
| Float | 126,503,000 | 26,226,050 |
| Shares Held by Insiders | 1.54% | 4.85% |
| Shares Held by Institutions | 112.9% | 83.3% |
Taxes
| Measure | Neogenomics | Industry median |
|---|---|---|
| Income Tax | -$2.67M | $1.36M |
Scores
| Measure | Neogenomics | Industry median |
|---|---|---|
| Altman Z-Score | 2.41 | 2.64 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Neogenomics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.